STCube's Innovative New Drug 'STT-003' Research Results Accepted at US 'AACR 2021'

[Asia Economy Reporter Yoo Hyun-seok] STCube, a bio company developing immune checkpoint inhibitors, announced on the 5th that it will present research results on the antibody ‘hSTC810’ targeting its pipeline ‘STT-003’ at the American Association for Cancer Research (AACR) conference to be held online in April.

The American Association for Cancer Research (AACR) is the world's largest annual cancer conference with participation from over 120 countries worldwide, where clinical research results on cancer are presented every year. At the upcoming ‘AACR 2021’, STCube plans to reveal for the first time the research results of its first-in-class innovative drug ‘STT-003’.

‘STT-003’, currently under development by STCube, is a novel immune checkpoint inhibitor targeting a previously unknown target. Unlike existing immune checkpoint inhibitor targets such as ‘PD-1’ and ‘PD-L1’, the research results on this new target will be presented for the first time in the world at this AACR event.

The antibody ‘hSTC810’ targeting ‘STT-003’ is expressed at limited levels in normal tissue cells but shows high expression rates in various cancer cells and is expressed in immune cells such as T lymphocytes at levels similar to PD-1. Through multiple animal experiments, it was identified as a substance that inhibits the immune regulatory molecule ‘STT-003’, which comprehensively suppresses immune function in cancer patients.

Additionally, STCube’s research revealed that the ‘hSTC810’ antibody can be used as a monotherapy and also exhibits synergistic effects when combined with PD-1 and PD-L1 therapies.

An STCube representative stated, "The ‘hSTC810’ antibody is expected to be effective not only in about 70% of patients who are non-responsive to currently marketed therapies ‘PD-1’ and ‘PD-L1’, but also in patients who have cancer cells without cancer progression or in those with recurrent cancer." They added, "This research presentation will serve as an opportunity to validate ‘STT-003’ at a global academic level ahead of its full-scale global Phase 1 clinical trial and to highlight the value of ‘STT-003’."

Meanwhile, the abstract that STCube will present at AACR is scheduled to be released on March 10, and ‘AACR 2021’ will be held online from April 9 to 14.